Nature Reviews Drug Discovery contents June 2016 Volume 15 Number 6 pp 369-440

If you are unable to see the message below, click here to view.

Advertisement
DOWNLOAD A WHITE PAPER THAT DESCRIBES THE EXQUISITE SPECIFICITY OF SOMAMER° REAGENTS, A UNIQUE CLASS OF PROTEIN AFFINITY MOLECULES  This white paper provides an overview of the specificity of protein-binding reagents in general, and more in-depth information regarding SOMAmer Reagents. You will also learn about the key differences between conventional aptamers, antibodies, and SOMAmers, primarily in multiplexing
TABLE OF CONTENTS
June 2016 Volume 15 Number 6
Impact Factor 41.908 *	In this issue Comment News and Analysis Research Highlights Perspectives Reviews Correspondence Also this month  Featured article: Convertible visceral fat as a therapeutic target to curb obesity Antonio Giordano, Andrea Frontini & Saverio Cinti
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
MicroRNAs: A Gene Silencing Mechanism with Therapeutic Implications July 13, 2016 This symposium, which features David Bartel, PhD of Whitehead/MIT/HHMI as Keynote Speaker, will present up-to-date basic, translational, and clinical research addressing the biology of miRNAs and their promise as therapeutic targets. Register here.
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
Subscribe to Nature with our best current personal subscription offer to access a wealth of scientific articles, features and news every week. Personal subscriptions include app, online, digital and print access so you can enjoy Nature anytime, anywhere.
Advertisement
BioPharma Dealmakers  A supplement to Nature Biotechnology & Nature Reviews Drug Discovery Sign up to our NEW networking forum to connect with life sciences companies and partnering professionals looking for dealmaking opportunities.  Stay up to date on emerging therapeutic areas  Ask for advice from our editors and experts in the field SIGN UP NOW
Comment: Key factors for successful data integration in biomarker research Antigoni Elefsinioti, Tanja Bellaire, Albert Wang, Karsten Quast, Henrik Seidel, Michael Braxenthaler, Gernot Goeller, Anastasia Christianson, David Henderson & Joachim Reischl p369 | doi:10.1038/nrd.2016.74 Integrating a wide range of biomedical data such as that rapidly emerging from the use of next-generation sequencing is expected to have a key role in identifying and qualifying new biomarkers to support precision medicine. Here, we highlight some of the challenges for biomedical data integration and approaches to address them. Abstract | Full Text | PDF | Supplementary information
NEWS AND ANALYSIS		Top
Reining in the supersized Phase I cancer trial Asher Mullard p371 | doi:10.1038/nrd.2016.110 Industry's overenthusiastic embrace of massive Phase I oncology trials is forcing oncologists and regulators to define the appropriate use of seamless clinical trials. PDF
Immuno-oncologists eye up macrophage targets Chris Morrison p373 | doi:10.1038/nrd.2016.111 Drugs that tap into macrophages' natural appetites, find ways to reduce their immunosuppressive effects or reduce their presence in the tumour milieu could complement existing immuno-oncology strategies. PDF
NEWS IN BRIEF FDA approves first drug for Parkinson disease psychosis Asher Mullard p375 | doi:10.1038/nrd.2016.114 PDF
Tackling antimicrobial drug resistance Asher Mullard p375 | doi:10.1038/nrd.2016.115 PDF
NCATS launches 'periodic table' for medicinal product ingredients Asher Mullard p375 | doi:10.1038/nrd.2016.116 PDF
BIOBUSINESS BRIEFS Regulatory watch: The orphan drug pipeline in Europe Thomas Morel, André Lhoir, Eline Picavet, Segundo Mariz, Bruno Sepodes, Jordi Llinares & David Cassiman p376 | doi:10.1038/nrd.2016.96 PDF
BIOBUSINESS BRIEFS Patent watch: Diagnostic patents at risk after Federal Circuit decisions Kevin Noonan p377 | doi:10.1038/nrd.2016.105 PDF
AN AUDIENCE WITH Alan Shuldiner p378 | doi:10.1038/nrd.2016.95 Alan Shuldiner, co-head of the Regeneron Genetics Center, says that the time for genomic drug discovery has arrived. PDF
FROM THE ANALYST'S COUCH Trends in clinical success rates Katarzyna Smietana, Marcin Siatkowski & Martin Møller p379 | doi:10.1038/nrd.2016.85 This analysis of the industry's clinical-stage portfolio in the past two decades reveals several trends, including a recent improvement in success rates in late-stage trials, an increase in overall portfolio size and higher success rates for biologics and partnered projects. PDF
RESEARCH HIGHLIGHTS Top Anticancer drugs: RAS mimetic revealed p381 | doi:10.1038/nrd.2016.108 PDF Metabolic disease: Novel fat-secreted hormone regulates glucose homeostasis p382 | doi:10.1038/nrd.2016.98 PDF Diabetes: Human iPSC-derived β-like cells rescue diabetic mice p382 | doi:10.1038/nrd.2016.99 PDF Infectious diseases: TIEing down vascular integrity during sepsis p383 | doi:10.1038/nrd.2016.106 PDF Neurodegenerative diseases: Laying the groundwork for remyelination p384 | doi:10.1038/nrd.2016.97 PDF IN BRIEF GPCRs: Glucagon receptor antagonist binding site identified | Cachexia: Inhibiting FAO rescues muscle-wasting | Pain: Blocking pain in inherited erythromelalgia | Cancer: Peptibodies rescue mice from lymphoma PDF Drug Discovery JOBS of the week Postdoctoral Fellowships in Cancer Immunotherapy and Drug Delivery Vanderbilt University Assistant / Associate Professors - Pharmaceutical Sciences Binghamton University Postdoctoral Associate Yale University Research Fellow in Structural Molecular Virology University of Leeds Associate Professor / Professor, Term Tenure Track / Term Tenure The University of Texas MD Anderson Cancer Center More Science jobs from Drug Discovery EVENT EuroUnion Drug Safety Congress 2016 12.10.16 London, UK More science events from
Advertisement
Droplet Digital™ PCR (ddPCR™) is leading the way  Droplet Digital PCR has led to more publications and discoveries than any other digital PCR platform - over 400 studies have taken advantage of ddPCR technology.  Find out how
PERSPECTIVES		Top
TIMELINE Ten years of anti-vascular endothelial growth factor therapy Napoleone Ferrara & Anthony P. Adamis p385 | doi:10.1038/nrd.2015.17 Over the past 10 years, targeting vascular endothelial growth factor A (VEGFA) has been widely pursued in the treatment of various cancers and ophthalmic diseases. Here, Ferrara and Adamis provide an overview of the discovery of VEGFA and the development of anti-VEGFA therapies, addressing key challenges and issues that remain in the application of these agents. Abstract | Full Text | PDF
Advertisement
Nature Outlook Open Innovation In the competitive world of drug discovery and development, secrecy is no longer as important as it was. As it has become more difficult and costly to produce therapies, competitors have begun to view greater collaboration and openness as a way to improve the efficiency of research. Available free online Produced with support from Boehringer Ingelheim
REVIEWS		Top
Convertible visceral fat as a therapeutic target to curb obesity Antonio Giordano, Andrea Frontini & Saverio Cinti p405 | doi:10.1038/nrd.2016.31 Current therapies for obesity have limited efficacy and may be associated with substantial adverse effects. Cinti and colleagues discuss the conversion of white fat to brown, thermogenic fat as a potential strategy to curb obesity. Adipocyte conversion could be particularly important in the visceral compartment, as fat in this region is associated with morbidity but is also particularly prone to transdifferentiation. Abstract | Full Text | PDF
Pursuit of a perfect insulin Alexander N. Zaykov, John P. Mayer & Richard D. DiMarchi p425 | doi:10.1038/nrd.2015.36 Insulin continues to represent a cornerstone therapy for diabetes, but its use is limited by its narrow therapeutic index. Here, DiMarchi and colleagues provide an overview of the history of the development and use of insulin as an antidiabetic agent, focusing on recent approaches to improve the efficacy, safety and convenience of insulin therapy. Abstract | Full Text | PDF
Erratum: Inhibiting fatty acid oxidation blocks tumour growth Sarah Crunkhorn p440 | doi:10.1038/nrd.2016.107 Full Text | PDF
Erratum: European Lead Factory hits its stride Katie Kingwell p440 | doi:10.1038/nrd.2016.113 Full Text | PDF
CORRESPONDENCE		Top
Correspondence: Worldwide collaboration for orphan drug designation Segundo Mariz, James H. Reese, Kerstin Westermark, Lesley Greene, Takahiro Goto, Tatsuro Hoshino, Jordi Llinares-Garcia & Bruno Sepodes p440 | doi:10.1038/nrd.2016.80 Full Text | PDF
Advertisement
npj Vaccines is an online-only, open access, multidisciplinary journal dedicated to publishing cutting-edge research and development on human and veterinary vaccines. npj Vaccines is now open for submissions – explore the benefits of submitting your next manuscript to the journal.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2013 Journal Citation Report (Thomson Reuters, 2014)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.